Aptinyx Investor Relations Material
Latest events
Q3 2022
Aptinyx
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Aptinyx Inc
Access all reports
Aptinyx Inc. is a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders with unmet medical need. The Company's two clinical programs include APTX101, which is being developed as a monotherapy for adults with refractory or high risk myoclonic seizures and adults with refractory partial onset seizures (ROS), and APTX102, which is being developed as a monotherapy for the treatment of adults with drug-resistant epilepsy (RxR-XII)
Latest articles
Strong Opinions, Loosely Held: Pontus Dackmo on Flexibility and Market Psychology
After a two-decade career in finance, Pontus Dackmo co-founded Protean Funds Scandinavia in 2022, where he now serves as CEO and Investment Manager.
4 Sep 2024
Novo Nordisk: The Danish Pharmaceutical Titan Revolutionizing Global Healthcare
Novo Nordisk's rise to becoming Europe's largest company, reshaping global healthcare and Denmark's economy.
5 Sep 2024
The Toyota Way: Revolutionizing Global Manufacturing
Explore how Toyota's Lean Manufacturing and Kaizen principles revolutionized production and quality, setting global benchmarks for excellence.
2 Sep 2024
Ticker symbol
APTX
Country
🇺🇸 United States